Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 576,892 |
|
|||||
| News | - | ||||||
| Day High | 19.71 | Low High |
|||||
| Day Low | 18.95 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kura Oncology Inc | KURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.65 | 3.42% | 19.65 | 18:23:45 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.20 | 18.95 | 19.71 | 19.65 | 19.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,418 | 576,892 | $ 19.38 | $ 11,181,720 | - | 7.41 - 24.17 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:34:41 | 1 | $ 19.60 | USD |
Kura Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.5B | 76.14M | - | 0 | -152.63M | -2.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kura Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.61 | 19.71 | 16.79 | 18.33 | 1,231,762 | 2.04 | 11.58% |
| 1 Month | 21.19 | 21.89 | 16.79 | 19.11 | 871,294 | -1.54 | -7.27% |
| 3 Months | 20.98 | 24.17 | 16.79 | 20.68 | 949,274 | -1.33 | -6.34% |
| 6 Months | 7.67 | 24.17 | 7.52 | 16.93 | 1,225,009 | 11.98 | 156.19% |
| 1 Year | 10.86 | 24.17 | 7.41 | 14.48 | 997,015 | 8.79 | 80.94% |
| 3 Years | 28.24 | 28.81 | 7.41 | 15.15 | 836,744 | -8.59 | -30.42% |
| 5 Years | 14.75 | 43.00 | 6.34 | 17.73 | 709,691 | 4.90 | 33.22% |
Kura Oncology Description
| Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. |
